Outcomes including local recurrence, distant metastases, and survival as well as toxicity data were modeled by a patient-level Markov microsimulation model, which were validated against trial data.

This study examines the availability of cost-effectiveness analyses for medical devices, both in terms of the number of studies and when studies are published. Objectives: Academic researchers and ...

Demand for humanitarian assistance is growing and existing financial resources are inadequate to address all areas of need. As stewards of limited funds, we have a responsibility to make the most ...

As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...

This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus. Objectives: In the United States, ...

Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...

This change, from April 2026, is designed to improve the operating environment for pharmaceutical companies in the UK to maximise the government’s commitment to unlock innovation and support the ...

Objective China has a high disease burden of low bone mass, and elderly men with excessive alcohol consumption may be underdiagnosed and undertreated given the adverse effects on skeletal health. This ...

Massachusetts legislators have drafted two bills that propose banning the use of cost-effectiveness analysis to inform healthcare coverage decisions. The proposals state that employing measures of ...